IIIrmgard Irminger-Finger

Irmgard Irminger-Finger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irmgard Irminger-Finger has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Luigi Atzori

    Clinical Metabolomics Unit, Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy

    2 shared publications
  • Alvin M. Malkinson

    Department of Pharmacological Science, University of Colorado Denver, Aurora, CO

    1 shared publication
  • Andrea Bianco

    Chair of Respiratory Diseases, Department of Health Sciences, University of Molise, Campobasso, Italy

    1 shared publication
  • D Kuester

    Institute of Pathology, Otto-von-Guericke University, Magdeburg, Germany

    1 shared publication
  • G Casula

    Department of Surgery, University of Cagliari, Cagliari, Italy

    1 shared publication
  • Geoffrey J. Laurent

    Centre for Respiratory Research, University College London, London, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome

    by Y-Q Zhang, M Pilyugin, D Kuester, V P Leoni, L Li, G Casula, L Zorcolo, R Schneider-Stock, L Atzori, I Irminger-Finger

    Background: Colon cancer predisposition is associated with mutations in BRCA1. BRCA1 protein stability depends on binding to BARD1. In different cancers, expression of differentially spliced BARD1 isoforms is correlated with poor prognosis and decreased patient survival. We therefore suspected a role of BARD1 isoforms in colon cancer. Methods: We performed immunohistochemistry in 168 colorectal cancers, using four antibodies directed against differentially expressed regions of BARD1. We determined structure and relative expression of BARD1 mRNA isoforms in 40 tumour and paired normal peri-tumour tissues. BARD1 expression was correlated with clinical outcome. Results: BARD1 isoforms were expressed in 98% of cases and not correlated with BRCA1. BARD1 mRNA isoforms were upregulated in all tumours as compared with paired normal peri-tumour tissues. Non-correlated expression and localisation of different epitopes suggested insignificant expression of full-length (FL) BARD1. Expression of N- and C-terminal epitopes correlated with increased survival, but expression of epitopes mapping to the middle of BARD1 correlated with decreased survival. Middle epitopes are present in oncogenic BARD1 isoforms, which have pro-proliferative functions. Correlated upregulation of only N- and C-terminal epitopes reflects the expression of isoforms BARD1δ and BARD1ϕ. Conclusion: Our results suggest that BARD1 isoforms, but not FL BARD1, are expressed in colon cancer and affect its progression and clinical outcome.


  • Open Access

    BARD1: An independent predictor of survival in non‐small cell lung cancer

    by Yong‐Qiang Zhang, Andrea Bianco, Alvin M. Malkinson, Vera Piera Leoni, Gianni Frau, Nicolina De Rosa, Pierre‐Alain André, Renato Versace, Michel Boulvain, Geoffrey J. Laurent, et al.

    BRCA1 mRNA overexpression is correlated with poor survival in NSCLC. However, BRCA1 functions depend on the interaction with BARD1 for its stability, nuclear localization and ubiquitin ligase activity. Expression of alternatively spliced BARD1 isoforms that lack the BRCA1‐interaction domain was found upregulated and correlated with poor prognosis in breast and ovarian cancer. These BARD1 isoforms are essential for proliferation of cancer cells in vitro. We investigated whether BARD1 isoforms are expressed in NSCLC. While in lung tissues from healthy controls BARD1 expression was undetectable on the mRNA level and protein level, we found two novel isoforms in addition to previously identified mRNAs expressed in all NSCLC samples tested. Furthermore, the pattern of BARD1 isoform expression was similar in tumor and morphologically normal peri‐tumor tissues, and only one novel isoform π was specifically upregulated in tumors. Immunohistochemistry revealed that all 100 NSCLC cases tested expressed isoform‐specific BARD1 epitopes, while BARD1 expression was undetectable in biopsies from healthy controls. Statistical analysis showed that the expression of epitopes PVC and WFS, present on isoform π, or epitope WFS alone, expressed on isoforms π, κ and β, were significantly correlated with decreased patient survival. These findings were corroborated in a mouse model of chemically induced lung cancer. Immunostaining of mouse tumors showed that BARD1 epitopes PVC and WFS were specifically upregulated in invasive, but not in confined lung tumors. Thus, BARD1 isoforms might be involved in tumor initiation and invasive progression and might represent a novel prognostic marker for NSCLC.


  • Preeclampsia: A danger growing in disguise

    by Irmgard Irminger-Finger, Nicole Jastrow, Olivier Irion